Patient and Provider Characteristics Associated With Sodium-Glucose Cotransporter 2 Inhibitor Prescription in Patients With Diabetes and Proteinuric Chronic Kidney Disease.
Journal
Clinical diabetes : a publication of the American Diabetes Association
ISSN: 0891-8929
Titre abrégé: Clin Diabetes
Pays: United States
ID NLM: 8406985
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
24
7
2020
Statut:
ppublish
Résumé
Despite accumulating evidence of cardiorenal benefits from sodium-glucose cotransporter 2 (SGLT2) inhibitors, prescription of agents in this drug class may be limited by concerns regarding adverse effects and interdisciplinary care coordination. To investigate these potential barriers, we performed a cross-sectional study of SGLT2 inhibitor prescriptions in 2017 in 3,779 adults with type 2 diabetes and proteinuric chronic kidney disease from a nationwide database. Only 173 (5%) of these patients received an SGLT2 inhibitor in 2017. Younger age, renin-angiotensin-aldosterone system inhibitor prescription, and higher estimated glomerular filtration rate were associated with SGLT2 inhibitor prescription. Primary care providers were responsible for the majority of the prescriptions. Continued efforts should be made to track and improve SGLT2 inhibitor use in indicated populations.
Identifiants
pubmed: 32699472
doi: 10.2337/cd19-0087
pii: CD190087
pmc: PMC7364452
doi:
Banques de données
figshare
['10.2337/figshare.12020976']
Types de publication
Journal Article
Langues
eng
Pagination
240-247Subventions
Organisme : NIDDK NIH HHS
ID : K01 DK110221
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK085446
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007357
Pays : United States
Informations de copyright
© 2020 by the American Diabetes Association.
Références
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Lancet. 2010 Nov 6;376(9752):1543-51
pubmed: 21055801
Diabetes Care. 2019 Jan;42(Suppl 1):S124-S138
pubmed: 30559237
Clin J Am Soc Nephrol. 2019 Sep 6;14(9):1306-1314
pubmed: 31405830
N Engl J Med. 2001 Sep 20;345(12):851-60
pubmed: 11565517
N Engl J Med. 2013 Dec 26;369(26):2492-503
pubmed: 24206459
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
N Engl J Med. 2008 Apr 10;358(15):1547-59
pubmed: 18378520
N Engl J Med. 2013 Nov 14;369(20):1892-903
pubmed: 24206457
N Engl J Med. 2012 Dec 6;367(23):2204-13
pubmed: 23121378
Diabetes Obes Metab. 2019 Nov;21(11):2394-2404
pubmed: 31264755
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Eur J Prev Cardiol. 2017 Oct;24(15):1637-1645
pubmed: 28870145
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
N Engl J Med. 2001 Sep 20;345(12):861-9
pubmed: 11565518
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
J Am Coll Cardiol. 2018 Dec 25;72(25):3370-3372
pubmed: 30409566
Am J Nephrol. 2017 Dec 13;46(6):462-472
pubmed: 29253846